ALB vs PKX

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong recent price run-up (+115.4% over 1Y), the company is unprofitable (negative profit and operating margins), has negative earnings growth (YoY), and trades at an extremely high forward P/E of 82.85. While the balance sheet shows a healthy current ratio and manageable debt/equity of 0.37, the lack of Altman Z-Score and Graham Number, combined with deteriorating profitability and insider selling, raises serious concerns about sustainability. The analyst target price of $165.06 implies 13% downside from current levels, reinforcing overvaluation relative to fundamentals.

PKX exhibits a significant disconnect between its market price and fundamental health, evidenced by a Piotroski F-Score of 4/9 (Stable/Weak) and a Graham Number of $32.96 against a current price of $78.71. While the stock has seen a massive 1-year price surge of 77.2%, this is not supported by profitability, as operating margins are nearly non-existent (0.16%) and the dividend payout ratio is unsustainable at 109.97%. The intrinsic value estimate of $10.85 suggests the stock is trading at a severe premium, likely based on speculative future growth rather than current earnings power.